{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:54:18Z","timestamp":1766400858381},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ejca.2015.10.013","type":"journal-article","created":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T07:16:36Z","timestamp":1451891796000},"page":"120-130","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care"],"prefix":"10.1016","volume":"54","clinical-trial-number":[{"clinical-trial-number":"nct00838370","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Didier","family":"Meulendijks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.G. Coen","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harm","family":"van Tinteren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemieke","family":"Cats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H.M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2015.10.013_bib1","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.10.013_bib2","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.10.013_bib3","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.10.013_bib4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/14740338.2010.511610","article-title":"Safety of capecitabine: a review","volume":"9","author":"Mikhail","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejca.2015.10.013_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1524-4733.2002.51083.x","article-title":"The incidence and cost of hospitalization for 5-FU toxicity among medicare beneficiaries with metastatic colorectal cancer","volume":"5","author":"Delea","year":"2002","journal-title":"Value Health"},{"key":"10.1016\/j.ejca.2015.10.013_bib6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"Van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2015.10.013_bib7","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","article-title":"Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity","volume":"13","author":"Prado","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2015.10.013_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N","article-title":"Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial","volume":"75","author":"Stein","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2015.10.013_bib9","article-title":"Upfront Genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","author":"Deenen","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.10.013_bib10","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejca.2015.10.013_bib11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2015.10.013_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2015.10.013_bib13","series-title":"R v.3.1.1. R: A language and environment for statistical computing","year":"2014"},{"key":"10.1016\/j.ejca.2015.10.013_bib14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.10.013_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","article-title":"Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients","volume":"49","author":"Poole","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2015.10.013_bib16","series-title":"Scientific Discussion Capecitabine","year":"2005"},{"key":"10.1016\/j.ejca.2015.10.013_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1365-2125.2003.01765.x","article-title":"Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients","volume":"55","author":"Gieschke","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2015.10.013_bib18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/BF00684885","article-title":"Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion","volume":"25","author":"Reece","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2015.10.013_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1015716617967","article-title":"Population pharmacokinetic analysis of the major metabolites of capecitabine","volume":"29","author":"Gieschke","year":"2002","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ejca.2015.10.013_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2125.2002.01598.x","article-title":"Relationships between body composition parameters and fluorouracil pharmacokinetics","volume":"54","author":"Gusella","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2015.10.013_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s002800051118","article-title":"Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic","author":"Cassidy","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2015.10.013_bib22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2004.07.121","article-title":"Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from intergroup trial 0114","volume":"22","author":"Meyerhardt","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.10.013_bib23","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/annonc\/mdl284","article-title":"Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer","volume":"17","author":"Gusella","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2015.10.013_bib24","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1200\/JCO.2005.02.167","article-title":"Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women","volume":"23","author":"Bajetta","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.10.013_bib25","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2013.172","article-title":"Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing","volume":"94","author":"Caudle","year":"2013","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915009272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915009272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T07:26:33Z","timestamp":1537082793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915009272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":25,"alternative-id":["S0959804915009272"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.10.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}